Overview

Cd33 car t-cells has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating cd33 car t-cells, 1 is phase 1/phase 2 (1 open).

CD33 Expression is the most frequent biomarker inclusion criterion for cd33 car t-cells clinical trials.

Acute myeloid leukemia is the most common disease being investigated in cd33 car t-cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cd33 Car T-Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cd33 car t-cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cd33cart

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.